PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

Topics: Clinical trial, Vaccination, Vaccine Pages: 7 (832 words) Published: April 15, 2014
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

On 01st FEB. 2014
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.  Buy this report OR know more: http://www.jsbmarketresearch.com/healthcare-medical/r-PharmaPoint-Prophylactic-Hepatitis-B-Virus-Vaccines-Global-Drug-Forecast-and-Market-Analysis-to-2022-89052 SCOPE

Overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. Annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HBV vaccine market. Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically Dynavax Technologies Heplisav and Sanofi Pasteur MSDs Hexyon. Analysis of the current and future market competition in the global HBV vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

TABLE OF CONTENT
1.2 List of Figures 20
 2 Introduction 22
 2.1 Catalyst 22
 2.2 Related Reports 23
 2.3 Upcoming Related Reports 24
 3 Disease Overview 25
 3.1 Overview 25
 3.2 Etiology and Pathophysiology 26
 3.2.1 Etiology 26
 3.2.2 Pathophysiology 30
 3.3 Symptoms 32
 3.4 Prognosis 34
 4 Vaccination Recommendations and Coverage Rates 35
 4.1 Overview 35
 4.2 US 38
 4.2.1 Immunization Recommendations and Policies 38
 4.2.2 Vaccination Coverage 40
 4.2.3 Clinical Practice 41
 4.3 France 43
 4.3.1 Immunization Recommendations and Policies 43
 4.3.2 Vaccination Coverage 44
 4.3.3 Clinical Practice 46
 4.4 Germany 47
 4.4.1 Immunization Recommendations and Policies 4
 4.4.2 Vaccination Coverage 48
 4.4.3 Clinical Practice 49
 4.5 Italy 51
 4.5.1 Immunization Recommendations and Policies 51
 4.5.2 Vaccination Coverage 52
 4.5.3 Clinical Practice 53
 4.6 Spain 55
 4.6.1 Immunization Recommendations and Policies 5
 4.6.2 Vaccination Coverage 56
 4.6.3 Clinical Practice 57
 4.7 UK 59
 4.7.1 Immunization Recommendations and Policies 59
 4.7.2 Vaccination Coverage 60
 4.7.3 Clinical Practice 61
 4.8 Japan 62...
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • PharmaPoint: Ulcerative Colitis
  • Hepatitis b Essay
  • Hepatitis B Essay
  • Essay about Servo Motors and Drives Market
  • Essay about HEPATITIS B
  • Hepatitis B Research Paper
  • JSB Market Research: PharmaPoint: Dry Eye Syndrome
  • Essay on JSB Market Research: PharmaPoint: Ulcerative Colitis

Become a StudyMode Member

Sign Up - It's Free